UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value BMEA The Nasdaq Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value BMEA The Nasdaq Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40335 Biomea Fusion, Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-2520134 (State or other jurisdiction of ...

Financial Performance - As of September 30, 2021, the company had an accumulated deficit of $35.0 million and incurred net losses of $12.6 million and $26.9 million for the three and nine months ended September 30, 2021, respectively[97]. - The company expects to continue incurring significant losses for the foreseeable future as it advances its research and development efforts and seeks regulatory approvals[99]. - Net cash used in operating activities was $19.5 million for the nine months ended September 30, 2021, primarily due to a net loss of $26.9 million[118]. - The impact of the COVID-19 pandemic may exacerbate the company's funding requirements and operational challenges[114]. Research and Development - Research and development expenses were $7.9 million for the three months ended September 30, 2021, compared to $0.8 million for the same period in 2020, representing an increase of $7.1 million[108]. - Research and development expenses for the nine months ended September 30, 2021, were $16.9 million, compared to $1.3 million for the same period in 2020, reflecting increased preclinical development costs[108]. - The company is developing its lead product candidate, BMF-219, for the treatment of liquid and solid tumors, with FDA clearance for its first Phase I trial announced in September 2021[96]. - The company has initiated preclinical work to assess the potential of the menin pathway in type 2 diabetes and expects to report findings in the first quarter of 2022[97]. Operating Expenses - Total operating expenses for the three months ended September 30, 2021, were $12.6 million, an increase of $11.5 million compared to $1.1 million for the same period in 2020[107]. - The company anticipates that general and administrative expenses will increase substantially due to staff expansion and costs associated with being a public company[105]. - General and administrative expenses increased to $4.8 million for the three months ended September 30, 2021, from $0.3 million in the same period of 2020, primarily due to increased personnel-related expenses and corporate costs[110]. Capital and Financing - The company completed its initial public offering in April 2021, issuing 9,000,000 shares at a price of $17.00 per share, raising approximately $152.8 million net of underwriting discounts and commissions[99]. - Net cash provided by financing activities was $152.9 million for the nine months ended September 30, 2021, primarily from the IPO proceeds[121]. - The company anticipates needing to raise substantial additional capital to fund product development and operations, with requirements depending on various factors including clinical trials and regulatory reviews[112]. Cash Position - As of September 30, 2021, the company had cash, cash equivalents, restricted cash, and investments totaling $191.9 million, with an accumulated deficit of $35.0 million[111]. - The company held $191.9 million in cash and cash equivalents as of September 30, 2021, with no interest-bearing liabilities[126]. Lease Obligations - Monthly lease payments for new lab space in San Carlos, California, are $57,638 with annual increases of 3%[122].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40335 Biomea Fusion, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 82-2520134 ( State or other jurisdiction ...

Financial Performance - The company reported a net loss of $5.9 million for the three months ended March 31, 2021, compared to a net loss of $0.4 million for the same period in 2020, representing an increase in losses of $5.5 million [112]. - The company had an accumulated deficit of $14.0 million as of March 31, 2020, primarily due to research and development and general administrative expenses [102]. - Net cash used in operating activities was $4.1 million for the three months ended March 31, 2021, primarily due to a net loss of $5.9 million [121]. - Cash provided by financing activities was $3,000 for the three months ended March 31, 2021 [123]. Research and Development - Research and development expenses increased to $3.8 million for the three months ended March 31, 2021, from $0.3 million in the same period in 2020, primarily due to increased preclinical development costs [113]. - The company expects to continue incurring significant operating losses and increasing expenses as it advances its research and development efforts, including the submission of INDs for product candidates [102]. - The company anticipates substantial increases in research and development expenses as it initiates and completes clinical trials for its product candidates [107]. - The company plans to file an IND with the FDA for its lead product candidate, BMF-219, in the second half of 2021 [102]. General and Administrative Expenses - General and administrative expenses rose to $2.1 million for the three months ended March 31, 2021, compared to $0.1 million in the same period in 2020, driven by increased personnel and professional services expenses [114]. Capital and Financing - The company completed its IPO in April 2021, issuing 9,000,000 shares at $17.00 per share, resulting in net proceeds of approximately $152.8 million [104]. - As of March 31, 2021, the company had cash, cash equivalents, restricted cash, and investments totaling $57.5 million [115]. - The company had an accumulated deficit of $14.0 million and anticipates needing to raise substantial additional capital for product development and operations [116]. - The company expects to continue requiring additional capital through various financing methods, which may not be available on acceptable terms [116]. Cash Flow and Investments - Cash used in investing activities was $38.5 million for the three months ended March 31, 2021, mainly related to cash investments in securities [122]. - The company held $57.5 million in cash, cash equivalents, restricted cash, and investments as of March 31, 2021 [130]. Operational Considerations - The company relies on third parties for manufacturing and does not have its own manufacturing facilities [104]. - Future lease payments for office and lab space total $137,000 for leases expiring in 2021, with an additional $244,000 for a sublease agreement [124]. - The company entered into a promissory note for a $35,637 PPP Loan, which was fully repaid in Q2 2021 [119]. - The impact of the COVID-19 pandemic may exacerbate the company's capital requirements and operational challenges [116]. - The company has no off-balance sheet arrangements as of the reporting periods presented [125].